ABT 957

Drug Profile

ABT 957

Alternative Names: ABT-957

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class
  • Mechanism of Action Calpain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In adults) in USA
  • 30 Jun 2016 Abbvie terminates a phase I trial for Alzheimer's disease (In adults, In elderly) in USA (NCT02573740) due to insufficient target engagement of ABT 957 as per preclinical data
  • 14 Jun 2016 Abbvie discontinues a phase I trial for Alzheimer's disease (In adults, In elderly) in USA (NCT02220738)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top